KUWAIT: Dexcom, a global leader in continuous glucose monitoring (CGM), has officially launched the Dexcom G7 in Kuwait in partnership with the Central Circle Company. On the sidelines of the event, Fadi Gedeon, General Manager for the Middle East and North Africa of Dexcom, stated that the company is launching its latest diabetes technology in Kuwait, the Dexcom G7 continuous glucose monitoring (CGM) system sensors that provide 24-hour monitoring.
He indicated that this technology allows patients to have full control over their diabetes and helps predict glucose fluctuations or hypoglycemia early, thereby preventing potential episodes. Gedeon pointed out that the new sensors feature a simplified, single-step insertion process designed for ease of use, can be worn on multiple approved body sites, and is water resistant. He also highlighted the collaboration with Central Circle, Dexcom’s local partner, which oversees all local operations related to Dexcom in Kuwait, including distribution, logistics, regulatory coordination, and marketing.
For his part, Dr Ziad Al-Alyan, CEO of Central Circle Co., said that Central Circle has been a leading distribution company since 1979, committed to delivering the best healthcare technologies across all modalities and specialties from abroad to Kuwaiti patients and the Kuwaiti healthcare system. “Our latest collaboration is with Dexcom, one of the leading and most innovative companies in diabetes management. The launch of their new product, the Dexcom G7, is a testament to this partnership,” he noted. He continued that the Dexcom G7 is one of the most accurate continuous glucose monitoring (CGM) devices available, providing readings that closely match actual laboratory results.
Its precision is so advanced that it has become one of the first CGM devices approved by the US Food and Drug Administration (FDA) for use in children under the age of four, a significant milestone in pediatric diabetes care, stating: “We are proud to offer this groundbreaking technology to the Kuwaiti market and patients across the country.” In his turn, Deputy CEO of Central Circle, Tareq Alaryan, said that the event marked the introduction of one of the latest and most advanced medical technologies in real-time glucose monitoring, explaining that the new model features a smaller, more comfortable design, and is globally approved for both children and adults.
Alaryan emphasized that Central Circle Company hopes this launch will be a positive step that benefits the community and contributes to better health for all. Meanwhile, Bassem Ashoush, Vice President of Medical Consumables and Consumer at Central Circle Company, explained that patients can monitor their glucose levels through an app compatible with all smartphones (Android and iPhone), which sends immediate alerts to patients when their blood glucose drops or is predicted to drop, reducing the risk of sudden hypoglycemia and the likelihood of hospitalization.
He revealed that Dexcom will be providing services to the Ministry of Health beyond patients’ expectation to empower users with greater clarity and control. According to local and international health data that the prevalence of diabetes in Kuwait reaches 24 peregrine, and many cases remain undiagnosed. This technology represents an important step toward better disease management and reducing poorly controlled cases. Alia Safi, Head of Marketing for MENA at Dexcom, shared her excitement about the launch of Dexcom G7 in Kuwait, noting that diabetes has a significant impact in Kuwait due to lifestyle and ethnicity factors, contributing to increased burdens and cardiovascular complications when glucose levels are not properly managed.
She added: “This motivated Dexcom to introduce its latest technology for all age groups, including pediatric, adolescent, adult, and geriatric patients.” Alia also highlighted Dexcom’s long history of innovation. An American company, Dexcom began developing its pipeline in the 1960s, with over 39 years of continuous innovation. The company launched its first continuous glucose monitor (CGM) in 1999, marking the introduction of the CGM concept to the market.
Initially focused in the United States, Dexcom has expanded globally over the past six years, including a presence in the Middle East over the last two years. She added: “Specifically in Kuwait, Dexcom has been present for some time, and the company is now bringing additional expertise to the country through its regional headquarters in the Middle East, supporting both the Middle East and Africa markets.”
